Jason Westin Selected Research

Lymphoma (Lymphomas)

1/2023	A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
1/2020	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
1/2020	CAR T-Cells.
1/2020	Primary CNS lymphoma commonly expresses immune response biomarkers.
1/2019	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.
1/2018	Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
1/2017	Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.
5/2015	Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason Westin Research Topics

Disease

28	B-Cell Lymphoma (Lymphoma, B Cell) 03/2024 - 05/2015
17	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2023 - 01/2010
12	Neoplasms (Cancer) 01/2023 - 08/2014
8	Lymphoma (Lymphomas) 01/2023 - 05/2015
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2024 - 01/2016
7	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2021 - 11/2013
3	Hematologic Neoplasms (Hematological Malignancy) 11/2022 - 01/2019
3	cell-associated neurotoxicity 01/2022 - 01/2020
2	Infections 11/2022 - 01/2016
2	Cytokine Release Syndrome 01/2022 - 01/2022
2	Hodgkin Disease (Hodgkin's Disease) 01/2020 - 01/2019
2	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2019 - 01/2019
1	Inflammation (Inflammations) 01/2023
1	Persistent Infection 11/2022
1	Viremia 11/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2022
1	Critical Illness (Critically Ill) 01/2022
1	Disease Progression 01/2022
1	Cytopenia 10/2021
1	Long Term Adverse Effects 10/2021
1	Opportunistic Infections (Opportunistic Infection) 10/2021
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2021
1	Pancytopenia 01/2021
1	Poisoning 01/2021
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020
1	Leukemia 01/2020
1	Microsatellite Instability 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Anemia 07/2017
1	Plasmablastic Lymphoma 03/2016
1	Atrial Fibrillation 01/2016
1	Hemorrhage 01/2016
1	Lymphocytosis 01/2016

Drug/Important Bio-Agent (IBA)

15	Chimeric Antigen ReceptorsIBA 11/2023 - 01/2018
10	axicabtagene ciloleucelIBA 03/2024 - 01/2020
10	Rituximab (Mabthera)FDA Link 01/2023 - 11/2013
7	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021 - 11/2013
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 11/2013
5	Vincristine (Oncovin)FDA LinkGeneric 11/2021 - 11/2013
4	ibrutinibIBA 01/2023 - 08/2014
4	Prednisone (Sone)FDA LinkGeneric 11/2021 - 08/2014
3	venetoclaxIBA 11/2021 - 01/2018
3	Etoposide (VP 16)FDA LinkGeneric 11/2021 - 05/2015
2	brexucabtagene autoleucelIBA 01/2024 - 01/2021
2	RNA (Ribonucleic Acid)IBA 11/2023 - 01/2020
2	Lenalidomide (CC 5013)FDA Link 01/2023 - 01/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2019
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 01/2018
2	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2020
1	Small Cytoplasmic RNAIBA 11/2023
1	Peptidoglycan (Murein)IBA 01/2023
1	PolyaminesIBA 11/2022
1	Ribavirin (Virazole)FDA LinkGeneric 11/2022
1	Antiviral Agents (Antivirals)IBA 11/2022
1	Immunoglobulin G (IgG)IBA 11/2022
1	Monoclonal AntibodiesIBA 01/2022
1	PlatinumIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	tazemetostatIBA 01/2022
1	atezolizumabIBA 01/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2022
1	OligonucleotidesIBA 01/2022
1	PNT100IBA 01/2022
1	Cell-Free Nucleic AcidsIBA 01/2022
1	tocilizumab (atlizumab)FDA Link 01/2022
1	A-Form DNA (A-DNA)IBA 01/2022
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 12/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2021
1	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2021
1	Mustard Gas (Sulfur Mustard)IBA 01/2021
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	AntigensIBA 01/2020
1	N 30IBA 01/2020
1	romidepsin (FK228)FDA Link 01/2020
1	tisagenlecleucelIBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	MLN 8237IBA 01/2020
1	Dacarbazine (DIC)FDA LinkGeneric 01/2020
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2020
1	Melphalan (Alkeran)FDA LinkGeneric 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Immunoglobulin M (IgM)IBA 01/2019
1	FM 100 (FM100)IBA 01/2019
1	fludarabineIBA 01/2019
1	Proteasome InhibitorsIBA 01/2018
1	ixazomibIBA 01/2018
1	Interferon-gamma (Interferon, gamma)IBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Bortezomib (Velcade)FDA Link 01/2017
1	Cyclin D1IBA 01/2016
1	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 07/2015

Therapy/Procedure

26	Therapeutics 03/2024 - 01/2010
12	Radiotherapy 01/2020 - 05/2015
8	Drug Therapy (Chemotherapy) 01/2023 - 11/2013
6	Stem Cell Transplantation 01/2023 - 10/2017
3	Immunotherapy 01/2023 - 01/2018
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Homologous Transplantation 01/2019